{"product_id":"kenvue-swot-analysis","title":"Kenvue SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrengthen Your Review with the Full SWOT Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eKenvue's consumer health portfolio offers meaningful brand strength and category breadth, while also exposing the company to competitive pressure and regulatory change. A clear SWOT review helps investors assess these strengths, weaknesses, and strategic risks with greater confidence.\u003c\/p\u003e\n\u003cp\u003eLooking for a deeper view of Kenvue's competitive position, risk profile, and growth drivers? Get the full SWOT analysis for a professionally written, fully editable report built to support investment review, strategic planning, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIconic and Trusted Brand Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue boasts an iconic and trusted brand portfolio, featuring household names like Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol. This diverse collection of well-established brands forms a powerful bedrock for sustained consumer loyalty and significant market presence. For example, in 2023, Kenvue reported approximately $15.4 billion in net sales, underscoring the market's reliance on these trusted brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue stands as the world's largest pure-play consumer health company, a powerful position built on substantial revenue and a truly global reach. This leadership is evidenced by its service to approximately 1.2 billion people across more than 165 countries, showcasing an unparalleled scale in the industry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScience-Backed Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue's strength lies in its science-backed innovation, with products like Neutrogena and Band-Aid frequently recommended by healthcare professionals. This deep connection to scientific research fosters significant consumer trust and sets Kenvue apart in a competitive market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Gross Profit Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKenvue demonstrated a strong performance in 2024, achieving a significant improvement in its gross profit margins, which expanded by 200 basis points. This enhancement is a direct result of the company's strategic focus on operational efficiency.\u003c\/p\u003e\n\u003cp\u003eThe gains in gross profit margin can be attributed to successful productivity improvements stemming from global supply chain optimization efforts. These initiatives streamlined operations and reduced costs, contributing to a healthier profit margin.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Kenvue effectively realized value through its pricing strategies. By implementing thoughtful pricing approaches, the company was able to translate product value into improved profitability.\u003c\/p\u003e\n\u003cp\u003eKey factors contributing to this strength include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e200 basis point expansion in gross profit margin in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eProductivity gains from global supply chain efficiency initiatives.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFavorable value realization through strategic pricing.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResilient Core Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKenvue's Self Care and Essential Health segments are proving to be strong performers, even when other parts of the business face headwinds. These areas are showing steady growth, providing a solid foundation for the company's financial stability.\u003c\/p\u003e\n\u003cp\u003eFor instance, in the first quarter of 2024, Kenvue reported that its Self Care business saw a 2.0% organic sales increase, driven by strong performance in pain care and digestive health. Similarly, Essential Health delivered a 1.5% organic sales growth during the same period, highlighting the consistent demand for these product categories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eResilient Self Care:\u003c\/strong\u003e This segment, featuring brands like Tylenol and Imodium, continues to exhibit robust organic sales growth, demonstrating consumer reliance on these trusted products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSteady Essential Health:\u003c\/strong\u003e The Essential Health division, encompassing products such as Aveeno and Band-Aid, also shows consistent positive momentum, contributing to overall revenue stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePillars of Financial Health:\u003c\/strong\u003e These core segments act as dependable revenue streams, offsetting potential volatility in other business units and supporting Kenvue's financial resilience.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Trust, Global Reach, and Efficiency Fueling Consumer Health Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue's strength is anchored in its extensive portfolio of globally recognized and trusted brands, including Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol. This powerful brand equity translates into significant consumer loyalty and a commanding market presence. The company's global scale is also a major asset, serving approximately 1.2 billion people in over 165 countries as the world's largest pure-play consumer health company.\u003c\/p\u003e\n\u003cp\u003eKenvue has demonstrated impressive operational efficiency, evidenced by a 200 basis point expansion in gross profit margins in 2024, driven by supply chain optimization and effective pricing strategies. This focus on productivity has directly improved profitability. Furthermore, key segments like Self Care and Essential Health show consistent organic sales growth, with Self Care up 2.0% and Essential Health up 1.5% in Q1 2024, providing a stable financial foundation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Strength\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Fact\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand Portfolio \u0026amp; Trust\u003c\/td\u003e\n\u003ctd\u003eIconic brands like Tylenol, Neutrogena, Aveeno\u003c\/td\u003e\n\u003ctd\u003eHigh consumer loyalty, market penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Scale\u003c\/td\u003e\n\u003ctd\u003eServes 1.2 billion people in 165+ countries\u003c\/td\u003e\n\u003ctd\u003eExtensive market reach, economies of scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Efficiency\u003c\/td\u003e\n\u003ctd\u003e200 bps gross profit margin expansion (2024)\u003c\/td\u003e\n\u003ctd\u003eImproved profitability, cost reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment Resilience\u003c\/td\u003e\n\u003ctd\u003eSelf Care +2.0% organic sales (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003eStable revenue, offsets other segment volatility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Kenvue's internal and external business factors, examining its strengths in established brands, weaknesses in recent spin-off challenges, opportunities in emerging markets, and threats from competition and regulatory changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eKenvue's SWOT analysis provides a clear roadmap for navigating market challenges and capitalizing on growth opportunities, easing the pressure of strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeclining Sales in Skin Health \u0026amp; Beauty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue's Skin Health \u0026amp; Beauty segment has faced significant headwinds, with declining sales and volume observed throughout 2024 and into the first quarter of 2025. This underperformance directly hinders the company's overall revenue growth trajectory.\u003c\/p\u003e\n\u003cp\u003eFor instance, the company reported a 2.1% organic sales decline in this category for the full year 2024, further exacerbated by a 3.5% drop in unit volume. This trend continued into Q1 2025, with Skin Health \u0026amp; Beauty sales falling by 4.8% organically.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNegative Foreign Currency Headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue has faced significant challenges due to unfavorable foreign currency movements, especially the strengthening U.S. dollar. This has directly impacted its reported net sales, creating a notable headwind for the company's financial performance.\u003c\/p\u003e\n\u003cp\u003eThe company has explicitly acknowledged these negative currency impacts, and they have been incorporated into its forward-looking financial projections. For instance, Kenvue's 2025 earnings outlook already accounts for the drag these currency headwinds are expected to impose on its results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoft Consumer Demand in Certain Categories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue has grappled with softer consumer demand in certain product categories. This subdued interest has impacted sales, particularly in areas sensitive to seasonal health trends.\u003c\/p\u003e\n\u003cp\u003eA prime example is the company's pediatric pain franchise, which saw a notable downturn in 2024. This decline was directly attributed to lower incidences of common childhood illnesses like colds, coughs, and flu, highlighting the impact of external health factors on demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Asset Impairments and Higher Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKenvue experienced a significant drag on its 2024 performance due to substantial non-cash charges stemming from asset impairments. These impairments directly reduced operating income, impacting the company's bottom line and overall profitability.\u003c\/p\u003e\n\u003cp\u003eHigher interest expenses in 2024 also played a crucial role in weakening Kenvue's financial results. This increase in borrowing costs eroded profitability further, contributing to a noticeable decline in diluted earnings per share for the period.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsset Impairments:\u003c\/strong\u003e Kenvue recorded significant non-cash charges in 2024 due to asset impairments, negatively affecting operating income.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased Interest Expenses:\u003c\/strong\u003e Higher borrowing costs in 2024 directly reduced profitability and diluted earnings per share.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProfitability Decline:\u003c\/strong\u003e The combined impact of these factors led to a weaker overall financial performance in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnsustainable Dividend Payout Ratio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKenvue's dividend payout ratio has reached an concerning 140%, signaling a potential unsustainability for its dividend payments without significant improvements in earnings. This elevated ratio suggests that the company is distributing more in dividends than it is earning, which is a red flag for long-term financial health.\u003c\/p\u003e\n\u003cp\u003eThis situation raises serious questions about the company's ability to maintain its current dividend levels moving forward, especially if earnings do not see a substantial uptick. Investors often view a payout ratio exceeding 100% as a sign of financial strain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnsustainable Dividend:\u003c\/strong\u003e Kenvue's dividend payout ratio stands at 140%, indicating it pays out more in dividends than it earns.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLong-Term Viability:\u003c\/strong\u003e This high ratio is not sustainable in the long run without considerable earnings growth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestor Concern:\u003c\/strong\u003e The current financial performance raises concerns about the reliability of future dividend payments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Decline and 140% Dividend Payout Raise Sustainability Concerns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue's Skin Health \u0026amp; Beauty segment is a significant weakness, experiencing a 2.1% organic sales decline in 2024 and a further 4.8% drop in Q1 2025, coupled with falling unit volumes. This underperformance directly impacts overall revenue growth. Additionally, unfavorable foreign currency movements, particularly a stronger U.S. dollar, have negatively affected reported net sales, a factor already accounted for in Kenvue's 2025 outlook. Softer consumer demand, exemplified by a downturn in the pediatric pain franchise in 2024 due to lower illness rates, also presents a challenge.\u003c\/p\u003e\n\u003cp\u003eThe company's financial health is further strained by substantial non-cash charges from asset impairments in 2024, which reduced operating income. Higher interest expenses in the same year also eroded profitability, contributing to a decline in diluted earnings per share. A critical concern is Kenvue's dividend payout ratio, which reached 140% in 2024, indicating that dividend payments exceed earnings, raising questions about long-term sustainability and investor confidence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment\/Factor\u003c\/td\u003e\n\u003ctd\u003e2024 Performance\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 Performance\u003c\/td\u003e\n\u003ctd\u003eImpact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkin Health \u0026amp; Beauty (Organic Sales)\u003c\/td\u003e\n\u003ctd\u003e-2.1%\u003c\/td\u003e\n\u003ctd\u003e-4.8%\u003c\/td\u003e\n\u003ctd\u003eHinders revenue growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnit Volume (Skin Health \u0026amp; Beauty)\u003c\/td\u003e\n\u003ctd\u003e-3.5%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eWeakens sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForeign Currency Impact\u003c\/td\u003e\n\u003ctd\u003eNegative\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eReduces reported net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric Pain Franchise\u003c\/td\u003e\n\u003ctd\u003eDownturn\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eAffected by lower illness rates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Impairments\u003c\/td\u003e\n\u003ctd\u003eSignificant non-cash charges\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eReduced operating income\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest Expenses\u003c\/td\u003e\n\u003ctd\u003eHigher\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eEroded profitability, reduced EPS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend Payout Ratio\u003c\/td\u003e\n\u003ctd\u003e140%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eUnsustainable, raises investor concern\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eKenvue SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Kenvue SWOT analysis document you'll receive upon purchase-no surprises, just professional quality and actionable insights.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version, offering a comprehensive understanding of Kenvue's strategic position.\u003c\/p\u003e\n\u003cp\u003eYou're viewing a live preview of the actual Kenvue SWOT analysis file. The complete version, detailing all strengths, weaknesses, opportunities, and threats, becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Cost-Saving Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue's 'Our Vue Forward' initiative targets approximately $350 million in annualized pre-tax gross cost savings by 2026. This strategic push aims to streamline operations and generate capital for future investments.\u003c\/p\u003e\n\u003cp\u003eThese cost-saving measures are crucial for enhancing Kenvue's financial flexibility, allowing for greater investment in innovation and market expansion in the competitive consumer health landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased Marketing and Innovation Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue is strategically boosting its investment in marketing and innovation, with a particular emphasis on its major brands. This increased focus is a key driver for accelerating future growth.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Kenvue reported a 4.9% increase in net sales, reaching $15.4 billion, partly fueled by these enhanced brand investments. The company is channeling resources into new product development and marketing campaigns to capture market share.\u003c\/p\u003e\n\u003cp\u003eThis commitment to innovation is crucial, especially as Kenvue aims to strengthen its portfolio of trusted consumer health products. By refreshing existing brands and introducing novel solutions, Kenvue is positioning itself for sustained competitive advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio Optimization through Strategic Review\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue's Board of Directors is actively engaged in a thorough review of strategic alternatives, a process that could lead to significant portfolio adjustments. This includes exploring options for simplifying its product offerings and streamlining operations to boost efficiency.\u003c\/p\u003e\n\u003cp\u003eThe primary goal of this strategic review is to unlock greater shareholder value and improve Kenvue's overall financial performance. For instance, a simplified portfolio might allow for more focused investment in high-growth segments, potentially increasing revenue streams.\u003c\/p\u003e\n\u003cp\u003eAs of early 2024, Kenvue's diverse portfolio spans consumer health categories like skincare, oral care, and self-care. The company generated approximately $15.4 billion in net sales in 2023, highlighting the scale of its operations and the potential impact of strategic optimization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into New Categories and Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKenvue has a significant opportunity to broaden its reach by entering rapidly expanding sectors within consumer health. This includes venturing into natural skincare, a market that saw substantial growth, with global natural skincare sales projected to reach over $30 billion by 2027. Additionally, there's potential in wellness products, an area consumers are increasingly investing in for preventative health measures. \u003c\/p\u003e\n\u003cp\u003eThe company can also capitalize on the burgeoning over-the-counter digital health solutions market. This segment is experiencing a surge in demand for telehealth services, remote monitoring, and digital therapeutics, offering a pathway to engage consumers through innovative technology. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpansion into Natural Skincare:\u003c\/strong\u003e Capitalize on the growing consumer preference for natural and organic ingredients, a trend that has driven significant market share gains for competitors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDevelopment of Wellness Products:\u003c\/strong\u003e Introduce new product lines focused on holistic well-being, including supplements, functional foods, and stress-management aids.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDigital Health Solutions:\u003c\/strong\u003e Leverage technology to offer accessible and convenient health management tools, such as symptom checkers, virtual consultations, and personalized health tracking apps.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeographic Market Expansion:\u003c\/strong\u003e Explore untapped or underdeveloped markets where consumer demand for Kenvue's product categories is on the rise, potentially through strategic partnerships or acquisitions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompletion of TSA Exits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe successful conclusion of Transition Services Agreements (TSAs) with Johnson \u0026amp; Johnson by mid-2025 presents a key opportunity for Kenvue. This complete separation is anticipated to streamline operations, leading to reduced costs and a more agile business structure. For instance, in the first quarter of 2024, Kenvue reported a reduction in selling, general, and administrative expenses, partly reflecting the ongoing unwinding of these agreements.\u003c\/p\u003e\n\u003cp\u003eThis independence allows Kenvue to fully control its strategic direction and operational efficiencies. The anticipated benefits include not only cost savings but also enhanced decision-making speed and greater focus on its core consumer health portfolio. Analysts project that the full exit from TSA-related services could contribute to a more favorable margin profile in the 2025 fiscal year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eReduced Operational Costs:\u003c\/strong\u003e The termination of TSA arrangements is expected to eliminate associated fees and overhead, directly impacting Kenvue's bottom line.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Independence:\u003c\/strong\u003e Full separation from Johnson \u0026amp; Johnson's service structures allows Kenvue to operate with greater autonomy and strategic flexibility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImproved Efficiency:\u003c\/strong\u003e Streamlining operations post-TSA completion is projected to boost overall business efficiency and responsiveness to market dynamics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlocking Growth: Skincare, Wellness, Digital Health \u0026amp; Independence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue has a significant opportunity to tap into the growing natural skincare market, which is projected to exceed $30 billion globally by 2027. The company can also expand into wellness products, catering to increasing consumer interest in preventative health. Additionally, Kenvue is well-positioned to capitalize on the digital health solutions sector, offering innovative tools for health management.\u003c\/p\u003e\n\u003cp\u003eThe complete separation from Johnson \u0026amp; Johnson's Transition Services Agreements (TSAs) by mid-2025 represents a key opportunity. This independence is expected to reduce operational costs and enhance Kenvue's strategic flexibility and decision-making speed. Analysts anticipate a positive impact on Kenvue's margin profile in fiscal year 2025 due to these streamlined operations.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpportunity Area\u003c\/td\u003e\n\u003ctd\u003eMarket Potential\u003c\/td\u003e\n\u003ctd\u003eKenvue's Strategic Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNatural Skincare\u003c\/td\u003e\n\u003ctd\u003eGlobal market projected over $30 billion by 2027\u003c\/td\u003e\n\u003ctd\u003eLeverage existing brand equity and distribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWellness Products\u003c\/td\u003e\n\u003ctd\u003eGrowing consumer investment in preventative health\u003c\/td\u003e\n\u003ctd\u003eIntroduce new product lines focusing on holistic well-being\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital Health Solutions\u003c\/td\u003e\n\u003ctd\u003eSurging demand for telehealth and personalized health tracking\u003c\/td\u003e\n\u003ctd\u003eDevelop accessible and convenient health management tools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-TSA Independence\u003c\/td\u003e\n\u003ctd\u003eElimination of associated fees and overhead; enhanced agility\u003c\/td\u003e\n\u003ctd\u003eStreamlined operations, improved efficiency, and greater strategic autonomy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competitive Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue navigates a fiercely competitive global consumer health sector, with major players like Haleon posing a significant challenge. This intense rivalry demands constant product development, robust marketing campaigns, and streamlined operational efficiencies to secure and grow its market position.\u003c\/p\u003e\n\u003cp\u003eIn 2023, the global consumer health market was valued at approximately $311 billion, a figure projected to grow. Kenvue's ability to differentiate its offerings, particularly in pain care and skin health where it holds leading positions, will be crucial against competitors investing heavily in R\u0026amp;D and market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic Headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKenvue faces significant challenges from ongoing macroeconomic headwinds. Persistent inflation in 2024 and into 2025 is driving up the cost of raw materials and manufacturing, directly impacting Kenvue's operational expenses and potentially squeezing profit margins. \u003c\/p\u003e\n\u003cp\u003eFurthermore, shifts in consumer spending habits, influenced by economic uncertainty and cost-of-living concerns, could dampen demand for Kenvue's products, especially discretionary items within its portfolio. For instance, while essential personal care items might show resilience, categories like premium skincare could see reduced consumer outlay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTariff Impacts and Supply Chain Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue's financial projections for 2025 anticipate that U.S. tariffs could add to their operational costs. This means higher expenses are on the horizon, directly impacting their bottom line.\u003c\/p\u003e\n\u003cp\u003eBeyond tariffs, persistent supply chain challenges are a significant concern. These ongoing pressures could further inflate costs and, critically, create potential shortages or delays in getting their products to consumers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActivist Investor Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKenvue is experiencing significant pressure from activist investors, notably Starboard Value, who are pushing for substantial strategic realignments. This pressure is particularly focused on the Skin Health \u0026amp; Beauty segment, with potential implications for divestitures or a reorientation of Kenvue's overall business strategy.\u003c\/p\u003e\n\u003cp\u003eActivist demands could force Kenvue to make difficult decisions regarding its portfolio. For instance, Starboard Value has reportedly urged Kenvue to consider divesting its consumer health business, a move that would fundamentally alter the company's structure and focus.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eActivist Influence:\u003c\/strong\u003e Starboard Value, a prominent activist investor, has taken a stake in Kenvue, signaling an intent to influence management decisions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Overhaul:\u003c\/strong\u003e The core demand revolves around a strategic review, with a particular emphasis on optimizing the Skin Health \u0026amp; Beauty division.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential Divestitures:\u003c\/strong\u003e Investors are advocating for the potential sale of underperforming or non-core assets to unlock shareholder value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManagement Response:\u003c\/strong\u003e Kenvue's management will need to carefully consider and respond to these demands, balancing activist expectations with long-term business sustainability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRisks Associated with Leadership Transition and Strategic Review\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKenvue faces significant threats from its recent leadership changes and ongoing strategic review. The appointment of a new CEO, effective January 2024, coupled with a comprehensive review of its business strategy, introduces inherent uncertainty. Investors and stakeholders will be closely watching to see how effectively the new leadership navigates this period of transition and strategic recalibration, as missteps could impact Kenvue's market position and financial performance.\u003c\/p\u003e\n\u003cp\u003eThe success of these transitions is paramount for Kenvue's long-term stability. A poorly managed leadership handover or a flawed strategic review could lead to:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiverted management focus\u003c\/strong\u003e from core business operations and innovation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential shifts in strategic direction\u003c\/strong\u003e that may not resonate with market demands or investor expectations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased operational costs\u003c\/strong\u003e associated with restructuring or implementing new strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNegative market sentiment\u003c\/strong\u003e and potential stock price volatility if the transitions are perceived as unstable or the strategic review yields unfavorable outcomes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKenvue Navigates Market Rivals, Economic Headwinds, and Investor Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKenvue operates in a highly competitive consumer health market, facing pressure from rivals like Haleon. Economic headwinds, including inflation in 2024 and 2025, are increasing operational costs and potentially impacting consumer spending on discretionary items. Furthermore, Kenvue is subject to activist investor pressure, such as from Starboard Value, advocating for strategic changes, including potential divestitures, which could reshape the company's structure and focus.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53660809396566,"sku":"kenvue-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/kenvue-swot-analysis.webp?v=1778889235","url":"https:\/\/balancedscorecardexamples.com\/products\/kenvue-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}